These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37122097)

  • 21. Tau liquid-liquid phase separation: At the crossroads of tau physiology and tauopathy.
    Islam M; Shen F; Regmi D; Petersen K; Karim MRU; Du D
    J Cell Physiol; 2024 Jun; 239(6):e30853. PubMed ID: 35980344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
    Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tau as a therapeutic target for Alzheimer's disease.
    Boutajangout A; Sigurdsson EM; Krishnamurthy PK
    Curr Alzheimer Res; 2011 Sep; 8(6):666-77. PubMed ID: 21679154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tetrandrine ameliorates cognitive deficits and mitigates tau aggregation in cell and animal models of tauopathies.
    Tong BC; Huang AS; Wu AJ; Iyaswamy A; Ho OK; Kong AH; Sreenivasmurthy SG; Zhu Z; Su C; Liu J; Song J; Li M; Cheung KH
    J Biomed Sci; 2022 Oct; 29(1):85. PubMed ID: 36273169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting tauopathy with engineered tau-degrading intrabodies.
    Gallardo G; Wong CH; Ricardez SM; Mann CN; Lin KH; Leyns CEG; Jiang H; Holtzman DM
    Mol Neurodegener; 2019 Oct; 14(1):38. PubMed ID: 31640765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tau in Alzheimer disease and related tauopathies.
    Iqbal K; Liu F; Gong CX; Grundke-Iqbal I
    Curr Alzheimer Res; 2010 Dec; 7(8):656-64. PubMed ID: 20678074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tauopathy: A common mechanism for neurodegeneration and brain aging.
    Saha P; Sen N
    Mech Ageing Dev; 2019 Mar; 178():72-79. PubMed ID: 30668956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of microtubule assembly competent tubulin synthesis leads to accumulation of phosphorylated tau in neuronal cell bodies.
    Fujiwara H; Watanabe S; Iwata M; Ueda S; Nobuhara M; Wada-Kakuda S; Misonou H; Miyasaka T
    Biochem Biophys Res Commun; 2020 Jan; 521(3):779-785. PubMed ID: 31699369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.
    Xiong Y; Zhao K; Wu J; Xu Z; Jin S; Zhang YQ
    Proc Natl Acad Sci U S A; 2013 Mar; 110(12):4604-9. PubMed ID: 23487739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tau Seeding Mouse Models with Patient Brain-Derived Aggregates.
    Robert A; Schöll M; Vogels T
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological Alterations of Tau in Alzheimer's Disease and 3xTg-AD Mouse Brains.
    Li L; Jiang Y; Hu W; Tung YC; Dai C; Chu D; Gong CX; Iqbal K; Liu F
    Mol Neurobiol; 2019 Sep; 56(9):6168-6183. PubMed ID: 30734228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy.
    Soler H; Dorca-Arévalo J; González M; Rubio SE; Ávila J; Soriano E; Pascual M
    Neurobiol Aging; 2017 Jan; 49():40-51. PubMed ID: 27743524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
    Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
    Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
    Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
    Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Degradation or aggregation: the ramifications of post-translational modifications on tau.
    Park S; Lee JH; Jeon JH; Lee MJ
    BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
    Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
    Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of tau hyperphosphorylation in canine dementia resembles early Alzheimer's disease and other tauopathies.
    Abey A; Davies D; Goldsbury C; Buckland M; Valenzuela M; Duncan T
    Brain Pathol; 2021 Jan; 31(1):144-162. PubMed ID: 32810333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tau, tau kinases, and tauopathies: An updated overview.
    Montalto G; Ricciarelli R
    Biofactors; 2023; 49(3):502-511. PubMed ID: 36688478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired tau-microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations.
    Xia Y; Sorrentino ZA; Kim JD; Strang KH; Riffe CJ; Giasson BI
    J Biol Chem; 2019 Nov; 294(48):18488-18503. PubMed ID: 31653695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.